BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 8334889)

  • 1. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.
    Song S; Chen JK; Lu CH; Yang PJ; Yang QY; Fan BC; He ML; Gui YL; Li LM; Fotherby K
    Contraception; 1993 Jun; 47(6):527-37. PubMed ID: 8334889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of injectable norethisterone oenanthate on ovarian hormones in Thai women.
    Werawatgoompa S; Vaivanijkul B; Leepipatpaiboon S; Channiyom K; Virutamasen P; Dusitsin N
    Contraception; 1980 Mar; 21(3):299-309. PubMed ID: 7389353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovulation inhibition following vaginal administration of pills containing norethindrone and mestranol.
    Coutinho EM; Silva AR; Carreira C; Barbosa I
    Contraception; 1984 Feb; 29(2):197-202. PubMed ID: 6723313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subdermal norethindrone pellets -- a method for contraception?
    Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
    Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norethisterone contraceptive microspheres.
    Rivera R; Alvarado G; Flores C; Aldaba S; Hernandez A
    J Steroid Biochem; 1987; 27(4-6):1003-7. PubMed ID: 3695501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
    Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
    Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of different doses of norethisterone oenanthate.
    Fotherby K; Hamawi A; Howard G; Bye PG; Elder M
    Contraception; 1984 Apr; 29(4):325-33. PubMed ID: 6744856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of norethisterone (500 mcg) and ethinyl estradiol (35 mcg) capsules on the pituitary-ovarian axis.
    Nuttall ID; Elstein M; Fahmy DR
    Contraception; 1982 May; 25(5):463-9. PubMed ID: 6809424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum progesterone and norethisterone levels following injection of norethisterone enanthate in different sites and doses.
    Joshi JV; Hazari KT; Shah RS; Chadha UC; Chitlange S; Gokral JS; Arolkar SG
    Steroids; 1989 Jun; 53(6):751-61. PubMed ID: 2815152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and biological justifications for the use of Triella].
    McGuire JL; Pasquale SA; Castaigne JP
    Rev Fr Gynecol Obstet; 1986 Dec; 81(12):731-6. PubMed ID: 3823727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
    Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
    Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.